Leonardo Jaimes, MD

All articles by Leonardo Jaimes, MD

• UDCA linked to lower cancer risk in PBC

  UDCA use was associated with significantly lower risks of GI, liver and breast cancers in patients with PBC.

• Ductopenia in PBC signals worse outcomes

  Losing tiny bile ducts in the liver (ductopenia) could be a strong warning sign of worse outcomes in people with PBC.

• Microbial shifts in the gut-biliary axis may drive PBC

  The gut microbiota could play a bigger role in the development of liver and biliary diseases such as PBC than what was previously thought.

• Bile duct loss at diagnosis predicts outcomes in PBC

  The amount of bile duct loss at the time of diagnosis appears to closely correlate with prognosis in patients with PBC.

• Study indicates PPAR agonists are a safe, effective treatment for PBC

  Peroxisome proliferator-activated receptor (PPAR) agonists appear to be a safe and effective therapeutic alternative for patients with PBC.

• Intercept withdraws Ocaliva from US market after evidence of liver injury

  In a postmarketing clinical trial, patients with noncirrhotic PBC receiving Ocaliva showed significantly higher rates of liver transplant and death.

• Study finds prevalence of PBC has increased globally, especially in the Western Pacific

  The Western Pacific region experienced a marked increase in PBC prevalence in the last year, notes a new study.

• Volixibat for PBC-induced itching scores breakthrough therapy designation

  The FDA gave volixibat a special approval as a potential treatment for itching in patients with primary biliary cholangitis.

• Mapping PBC genetics: Which approach is better?

  A new study suggests which method is superior for detecting genetic variables associated with primary biliary cholangitis (PCB).

• FDA approves seladelpar to treat PBC

  The U.S. Food and Drug Administration gave accelerated approval for seladelpar to treat primary biliary cholangitis (PBC).